Header Logo

Connection

MICHAEL JAMES OVERMAN to Pyrrolidines

Back to Details
This is a "connection" page, showing publications MICHAEL JAMES OVERMAN has written about Pyrrolidines.
MICHAEL JAMES OVERMAN
Connection Strength
0.152
Pyrrolidines
  1. Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. Cancer Invest. 2008 Oct; 26(8):794-9.
    View in: PubMed
    Score: 0.077
  2. Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors. Invest New Drugs. 2008 Oct; 26(5):445-54.
    View in: PubMed
    Score: 0.075
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.